Forty-four MCAS patients had additional associated hematologic neoplasms, most frequently multiple myeloma, JAK2-positive essential thrombocytosis, and chronic lymphocytic leukemia (Table 2). This evidence concerns the gene JAK2 and hematopoietic and lymphoid system neoplasm.